Table 1.
Clinicopathologic characteristics of patients
| Clinicopathologic variables |
Primary tumor | Primary tumor | Metastasis |
|---|---|---|---|
| Did not receive neoadjuvant therapy |
Received neoadjuvant therapy |
Lymph node | |
| (n = 12) | (n = 18) | (n = 1) | |
| Age (years) | |||
| Median (range) | 43 (33–61) | 47 (34–88) | 62 |
| Tumor size (cm) | |||
| Median (range) | 2.1 (0.8–3.2) | 3.7 (1.5–14.6) | 2.5 |
| Subtype | |||
| HR+/HER2− | 5 (42%) | 8 (44%) | 0 (0%) |
| HR+/HER2+ | 0 (0%) | 0 (0%) | 0 (0%) |
| HR−/HER2+ | 1 (8%) | 0 (0%) | 0 (0%) |
| TNBC | 6 (50%) | 10 (56%) | 1 (100%) |
| Histological type | |||
| IDC, NOS | 12 (100%) | 18 (100%) | 0 (0%) |
| Metaplastic carcinoma | 0 (0%) | 0 (0%) | 1 (100%) |
| Histological grade | |||
| 2 | 3 (25%) | 4 (22%) | 1 (100%) |
| 3 | 9 (75%) | 14 (78%) | 0 (0%) |
| LVI | |||
| Absent | 10 (83%) | 5 (28%) | NA |
| Present | 2 (17%) | 13 (72%) | |
| TNM stage | |||
| I | 5 (42%) | 2 (11%) | NA |
| II | 7 (58%) | 8 (44%) | |
| III | 0 (0%) | 8 (44%) | |
| IV | 0 (0%) | 0 (0%) | |
| Miller–Payne grade | |||
| 1 | 8 (44%) | ||
| 2 | 6 (33%) | ||
| 3 | 4 (22%) | ||
| RCB class | |||
| II | 7 (39%) | ||
| III | 11 (61%) | ||
HR hormone receptor, HER2 human epidermal growth factor receptor 2-positive, IDC invasive ductal carcinoma, LVI lymphovascular invasion, NA not available, NOS not otherwise specified, RCB residual cancer burden, TNBC triple-negative breast cancer